4,459
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study

, , , , , , , , , & show all
Pages 1005-1016 | Received 10 Jan 2023, Accepted 09 Mar 2023, Published online: 29 Mar 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Scott F. Huntington, Wendy Y. Cheng, Eric M. Sarpong, Siyang Leng, Mohammed Z. H. Farooqui, Uchechukwu Samuel Agu, Maryaline Catillon, Dominique Lejeune, Nathaniel Downes, Lisa Matay, Mei Sheng Duh & Enrico De Nigris. (2024) Real-world patterns and sequences of targeted therapy use in chronic lymphocytic leukemia and small lymphocytic lymphoma in the United States: a longitudinal study. Leukemia & Lymphoma 0:0, pages 1-11.
Read now

Articles from other publishers (6)

Thomas E. Lew, Rory Bennett, Victor S. Lin, Ashley Whitechurch, Sasanka M. Handunnetti, Paula Marlton, Yandong Shen, Stephen P. Mulligan, Joshua Casan, Piers Blombery, Constantine S. Tam, Andrew W. Roberts, John F. Seymour, Philip A. Thompson & Mary A. Anderson. (2024) Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon. Blood Advances 8:6, pages 1439-1443.
Crossref
Helen Ma, Susan O'Brien & Pankaj Gupta. (2024) Treatment Patterns and Outcomes in U.S. Military Veterans Diagnosed With Chronic Lymphocytic Leukemia (CLL). Clinical Lymphoma Myeloma and Leukemia 24:2, pages 77-82.
Crossref
Idanna Innocenti, Alberto Fresa, Annamaria Tomasso, Michela Tarnani, Laura De Padua, Giulia Benintende, Raffaella Pasquale, Eugenio Galli, Francesca Morelli, Diana Giannarelli, Francesco Autore & Luca Laurenti. (2023) Treatment Sequencing and Outcome of Chronic Lymphocytic Leukemia Patients Treated at Fondazione Policlinico Universitario Agostino Gemelli IRCCS: A Thirty-Year Single-Center Experience. Cancers 15:23, pages 5592.
Crossref
Tanya Siddiqi, David G Maloney, Saad S Kenderian, Danielle M Brander, Kathleen Dorritie, Jacob Soumerai, Peter A Riedell, Nirav N Shah, Rajneesh Nath, Bita Fakhri, Deborah M Stephens, Shuo Ma, Tatyana Feldman, Scott R Solomon, Stephen J Schuster, Serena K Perna, Sherilyn A Tuazon, San-San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen & William G Wierda. (2023) Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1–2 study. The Lancet 402:10402, pages 641-654.
Crossref
Skye Montoya & Meghan C. Thompson. (2023) Non-Covalent Bruton’s Tyrosine Kinase Inhibitors in the Treatment of Chronic Lymphocytic Leukemia. Cancers 15:14, pages 3648.
Crossref
Rory Bennett, Mary Ann Anderson & John F. Seymour. (2023) Unresolved questions in selection of therapies for treatment-naïve chronic lymphocytic leukemia. Journal of Hematology & Oncology 16:1.
Crossref